Skip to main content
OpenTrials
Completed

NCT Number: NCT04603378

A Clinical Study to Assess the Effect of Novel Glycans on Nitrogen Metabolism of the Gut in Healthy Subjects

This exploratory, randomized, double-blind, placebo-controlled study aims to explore the effect of novel glycans on nitrogen metabolism in the gut in healthy subjects using a stable isotope.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

PPD Phase I Clinic

Austin, Texas, 78744, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

To be eligible for inclusion, the patient must fulfill all of the following criteria at screening:

  • Willing to provide multiple stool samples
  • Be male or female, ≥18 and <50 years of age
  • Have a body mass index ≥18 and <50 kg/m2
  • No current renal, hepatic or metabolic disease, significant dyslipidemia, or infection
  • Willing to adhere to dietary requirements as stated in the protocol
  • Willing to continue usual exercise routine
  • Willing to continue taking any current supplements and vitamins (with the exception of prebiotic or probiotic supplements) that the subject is currently taking, for the duration of the study

Patients will be excluded from the study if they meet any of the following criteria at screening :

  • Currently taking probiotic or prebiotic dietary supplements, or have taken them in the past 28 days (prior to Screening Visit), or unwilling to avoid prebiotic or probiotic dietary supplements for the duration of the study
  • Currently taking, or have taken during the last seven days prior to enrollment, drugs or other compounds that modulate GI motility
  • Currently taking bismuth, or have taken bismuth within seven days prior to enrollment
  • Recent history (within six weeks of Screening Visit) of the following condition requiring medical attention or treatment, including over-the-counter medications: constipation, diarrhea, and/or acute GI illness.
  • Systemic antibiotics taken within the previous three months (prior to Screening Visit).
  • History of or active inflammatory bowel disease
  • History of or active irritable bowel syndrome
  • History of or active autoimmune disease.
  • History of or active GI malignancy.
  • Established pre-diabetic status (eg, multiple fasting blood glucose measurements 100 to 125 mg/dL inclusive, or history of failed glucose tolerance tests) and as assessed by HbA1c test.

Treatment and study plan

KB195

Other

KB195 is a novel glycan

Polydextrose

Other

Polydextrose is an oligosaccharide

Pullulan

Other

Pullulan is an oligosaccharide

maltodextrin

Other

Maltodextrin is a digestible carbohydrate

Primary outcomes

  1. Number of patients experiencing any treatment-emergent adverse events (TEAEs)

    Time frame: Day -8 to Day 29

Sponsors and collaborators

Lead sponsor

Kaleido Biosciences

Industry

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Novel Glycans on Nitrogen Metabolism of the Gut in Healthy Subjects Using a Stable Isotope

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Oct 26, 2020
Registry last updated
Oct 26, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.